Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 14/20 | 1.00 |
| ▸ | FCER2 | P06734 | 13/20 | 1.00 |
| ▸ | MMP2 | P08253 | 7/20 | 1.00 |
| ▸ | MMP3 | P08254 | 6/20 | 1.00 |
| ▸ | MMP7 | P09237 | 4/20 | 1.00 |
| ▸ | MMP8 | P22894 | 4/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 3/20 | 1.00 |
| ▸ | MMP9 | P14780 | 3/20 | 1.00 |
| ▸ | MMP13 | P45452 | 3/20 | 1.00 |
| ▸ | MMP14 | P50281 | 3/20 | 1.00 |
| ▸ | MMP12 | P39900 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Batimastat SCHEMBL22803645 | 1.00 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL20793035 | 1.00 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL4332 | 1.00 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL12336015 | 1.00 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL12561510 | 1.00 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL4333 | 1.00 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL17521974 | 1.00 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| SCHEMBL22847464 | 0.95 | MMP1 (0.91) | MMP1FCER2MMP2MMP3MMP7 | |
| SCHEMBL25602210 | 0.91 | MMP1 (0.83) | MMP1FCER2MMP2MMP3MMP7 | |
| SCHEMBL23258231 | 0.91 | MMP1 (0.86) | MMP1FCER2MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148179-A1 | SMALL MOLECULE INHIBITORS OF SARS-CoV-2 VIRAL REPLICATION AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| US-9550978-B2 | Isolation and functional identification of cells | CAPROTEC BIOANALYTICS GMBH (DE) | 2017-01-24 | — | — | US | disclosed |
| US-8119854-B2 | Role of proteoglycans in drug dependence | Sanna, Pietro P. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100199361-A1 | Role of Proteoglycans in Drug Dependence | Sanna, Pietro Paolo (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100199361-A1 | Role of Proteoglycans in Drug Dependence | OGFR, CSGALNACT1, OPRL1 | MMP1 1050/4885FCER2 1547/4885MMP2 773/4885 |
| US-20230148179-A1 | SMALL MOLECULE INHIBITORS OF SARS-CoV-2 VIRAL REPLICATION AND USES THEREOF | ACE2, ACE, SARS1 | MMP1 1601/4885FCER2 1518/4885MMP2 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.